New drug combo may boost stem cell transplant success in hard-to-treat blood cancers
NCT ID NCT07214064
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 31 times
Summary
This study tests whether adding venetoclax to the usual pre-transplant chemotherapy (treosulfan) can safely improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). About 27 adults aged 18–75 will receive this stronger conditioning before a donor stem cell transplant. The main goal is to see if more patients are alive 28 days after transplant without serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML - ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital , Department of Internal Medicine II
Tübingen, Baden-Wurttemberg, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.